Tiziana Life Sciences PLC (TILS) Given “Speculative Buy” Rating at Beaufort Securities
Beaufort Securities reissued their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:TILS) in a research report sent to investors on Monday. They currently have a GBX 400 ($5.31) target price on the biotechnology company’s stock.
Shares of Tiziana Life Sciences PLC (LON TILS) opened at 150.00 on Monday. The company has a 50-day moving average of GBX 154.01 and a 200-day moving average of GBX 179.35. Tiziana Life Sciences PLC has a 12-month low of GBX 102.06 and a 12-month high of GBX 240.00. The stock’s market capitalization is GBX 141.59 million.
Tiziana Life Sciences PLC (LON:TILS) last released its earnings results on Friday, September 29th. The biotechnology company reported GBX (4.10) (($0.05)) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (2) (($0.03)) by GBX (2.10) (($0.03)). Equities analysts expect that Tiziana Life Sciences PLC will post ($1.70) earnings per share for the current fiscal year.
About Tiziana Life Sciences PLC
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.